Cargando…

Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study

BACKGROUND: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid therapy, all of which can lead to metabolism disturbances, atherogenesis, and increased cardiovascular (CV) risk. The aim of this study was to assess the CV risk in II...

Descripción completa

Detalles Bibliográficos
Autores principales: Oreska, Sabina, Storkanova, Hana, Kudlicka, Jaroslav, Tuka, Vladimir, Mikes, Ondrej, Krupickova, Zdislava, Satny, Martin, Chytilova, Eva, Kvasnicka, Jan, Spiritovic, Maja, Hermankova, Barbora, Cesak, Petr, Rybar, Marian, Pavelka, Karel, Senolt, Ladislav, Mann, Herman, Vencovsky, Jiri, Vrablik, Michal, Tomcik, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118331/
https://www.ncbi.nlm.nih.gov/pubmed/35602501
http://dx.doi.org/10.3389/fmed.2022.861419
_version_ 1784710472484782080
author Oreska, Sabina
Storkanova, Hana
Kudlicka, Jaroslav
Tuka, Vladimir
Mikes, Ondrej
Krupickova, Zdislava
Satny, Martin
Chytilova, Eva
Kvasnicka, Jan
Spiritovic, Maja
Hermankova, Barbora
Cesak, Petr
Rybar, Marian
Pavelka, Karel
Senolt, Ladislav
Mann, Herman
Vencovsky, Jiri
Vrablik, Michal
Tomcik, Michal
author_facet Oreska, Sabina
Storkanova, Hana
Kudlicka, Jaroslav
Tuka, Vladimir
Mikes, Ondrej
Krupickova, Zdislava
Satny, Martin
Chytilova, Eva
Kvasnicka, Jan
Spiritovic, Maja
Hermankova, Barbora
Cesak, Petr
Rybar, Marian
Pavelka, Karel
Senolt, Ladislav
Mann, Herman
Vencovsky, Jiri
Vrablik, Michal
Tomcik, Michal
author_sort Oreska, Sabina
collection PubMed
description BACKGROUND: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid therapy, all of which can lead to metabolism disturbances, atherogenesis, and increased cardiovascular (CV) risk. The aim of this study was to assess the CV risk in IIM patients and healthy controls (HC), and its association with disease-specific features. METHODS: Thirty nine patients with IIM (32 females; mean age 56; mean disease duration 4.8 years; dermatomyositis: n = 16, polymyositis: n = 7, immune-mediated necrotizing myopathy: n = 8, anti-synthetase syndrome: n = 8) and 39 age-/sex-matched HC (32 females, mean age 56) without rheumatic diseases were included. In both groups, subjects with a history of CV disease (angina pectoris, myocardial infarction, cerebrovascular, and peripheral arterial vascular events) were excluded. Muscle involvement, disease activity, and tissue damage were evaluated (Manual Muscle Test-8, Myositis Intention to Treat Activity Index, Myositis Damage Index). Comorbidities and current treatment were recorded. All participants underwent examinations of carotid intima-media thickness (CIMT), pulse wave velocity (PWV), ankle-brachial index (ABI), and body composition (by densitometry and bioelectric impedance). The risk of fatal CV events was evaluated by the Systematic COronary Risk Evaluation (SCORE, charts for the European population) and its modifications. RESULTS: Compared to HC, there was no significant difference in IIM patients regarding blood pressure, ABI, PWV, CIMT, and the risk of fatal CV events by SCORE or SCORE2, or subclinical atherosclerosis (CIMT, carotid plaques, ABI, and PWV). The calculated CV risk scores by SCORE, SCORE2, and SCORE multiplied by the coefficient 1.5 (mSCORE) were reclassified according to the results of carotid plaque presence and CIMT; however, none of them was demonstrated to be significantly more accurate. Other significant predictors of CV risk in IIM patients included age, disease duration and activity, systemic inflammation, lipid profile, lean body mass, and blood pressure. CONCLUSIONS: No significant differences in CV risk factors between our IIM patients and HC were observed. However, in IIM, CV risk was associated with age, disease duration, duration of glucocorticoid therapy, lipid profile, and body composition. None of the currently available scoring tools (SCORE, SCORE2, mSCORE) used in this study seems more accurate in estimating CV risk in IIM.
format Online
Article
Text
id pubmed-9118331
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91183312022-05-20 Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study Oreska, Sabina Storkanova, Hana Kudlicka, Jaroslav Tuka, Vladimir Mikes, Ondrej Krupickova, Zdislava Satny, Martin Chytilova, Eva Kvasnicka, Jan Spiritovic, Maja Hermankova, Barbora Cesak, Petr Rybar, Marian Pavelka, Karel Senolt, Ladislav Mann, Herman Vencovsky, Jiri Vrablik, Michal Tomcik, Michal Front Med (Lausanne) Medicine BACKGROUND: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid therapy, all of which can lead to metabolism disturbances, atherogenesis, and increased cardiovascular (CV) risk. The aim of this study was to assess the CV risk in IIM patients and healthy controls (HC), and its association with disease-specific features. METHODS: Thirty nine patients with IIM (32 females; mean age 56; mean disease duration 4.8 years; dermatomyositis: n = 16, polymyositis: n = 7, immune-mediated necrotizing myopathy: n = 8, anti-synthetase syndrome: n = 8) and 39 age-/sex-matched HC (32 females, mean age 56) without rheumatic diseases were included. In both groups, subjects with a history of CV disease (angina pectoris, myocardial infarction, cerebrovascular, and peripheral arterial vascular events) were excluded. Muscle involvement, disease activity, and tissue damage were evaluated (Manual Muscle Test-8, Myositis Intention to Treat Activity Index, Myositis Damage Index). Comorbidities and current treatment were recorded. All participants underwent examinations of carotid intima-media thickness (CIMT), pulse wave velocity (PWV), ankle-brachial index (ABI), and body composition (by densitometry and bioelectric impedance). The risk of fatal CV events was evaluated by the Systematic COronary Risk Evaluation (SCORE, charts for the European population) and its modifications. RESULTS: Compared to HC, there was no significant difference in IIM patients regarding blood pressure, ABI, PWV, CIMT, and the risk of fatal CV events by SCORE or SCORE2, or subclinical atherosclerosis (CIMT, carotid plaques, ABI, and PWV). The calculated CV risk scores by SCORE, SCORE2, and SCORE multiplied by the coefficient 1.5 (mSCORE) were reclassified according to the results of carotid plaque presence and CIMT; however, none of them was demonstrated to be significantly more accurate. Other significant predictors of CV risk in IIM patients included age, disease duration and activity, systemic inflammation, lipid profile, lean body mass, and blood pressure. CONCLUSIONS: No significant differences in CV risk factors between our IIM patients and HC were observed. However, in IIM, CV risk was associated with age, disease duration, duration of glucocorticoid therapy, lipid profile, and body composition. None of the currently available scoring tools (SCORE, SCORE2, mSCORE) used in this study seems more accurate in estimating CV risk in IIM. Frontiers Media S.A. 2022-05-03 /pmc/articles/PMC9118331/ /pubmed/35602501 http://dx.doi.org/10.3389/fmed.2022.861419 Text en Copyright © 2022 Oreska, Storkanova, Kudlicka, Tuka, Mikes, Krupickova, Satny, Chytilova, Kvasnicka, Spiritovic, Hermankova, Cesak, Rybar, Pavelka, Senolt, Mann, Vencovsky, Vrablik and Tomcik. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Oreska, Sabina
Storkanova, Hana
Kudlicka, Jaroslav
Tuka, Vladimir
Mikes, Ondrej
Krupickova, Zdislava
Satny, Martin
Chytilova, Eva
Kvasnicka, Jan
Spiritovic, Maja
Hermankova, Barbora
Cesak, Petr
Rybar, Marian
Pavelka, Karel
Senolt, Ladislav
Mann, Herman
Vencovsky, Jiri
Vrablik, Michal
Tomcik, Michal
Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study
title Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study
title_full Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study
title_fullStr Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study
title_full_unstemmed Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study
title_short Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study
title_sort cardiovascular risk in myositis patients compared to the general population: preliminary data from a single-center cross-sectional study
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118331/
https://www.ncbi.nlm.nih.gov/pubmed/35602501
http://dx.doi.org/10.3389/fmed.2022.861419
work_keys_str_mv AT oreskasabina cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT storkanovahana cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT kudlickajaroslav cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT tukavladimir cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT mikesondrej cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT krupickovazdislava cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT satnymartin cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT chytilovaeva cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT kvasnickajan cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT spiritovicmaja cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT hermankovabarbora cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT cesakpetr cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT rybarmarian cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT pavelkakarel cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT senoltladislav cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT mannherman cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT vencovskyjiri cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT vrablikmichal cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy
AT tomcikmichal cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy